AmCad BioMed is the world’s first medical device company to receive FDA approval for its ultrasound computer-aided diagnosis (CAD) system. Combining AI and clinical expertise, AmCad has developed four FDA, CE, and TFDA-certified AI-assisted CAD software, including AmCAD-UT for thyroid nodule detection and AmCAD-UO for rapid OSA assessment. Driven by innovation, AmCad’s patented technologies have earned numerous accolades, empowering healthcare professionals with enhanced diagnostic quality and superior patient experiences. A pioneer in ultrasound AI, AmCad redefines diagnostic precision and patient care.